FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Immunoconjugate comprising a recombinant IgG1 antibody to the epidermal growth factor of a human (hEGFR) covalently attached to a cytotoxic agent has been proposed. Pharmaceutical composition comprising said immunoconjugate and a method of treating cancer are also described.
EFFECT: present invention can find application in the treatment of various cancers, including solid tumors such as glioma, epithelial tumor, breast tumor, lung tumor, prostate tumor, bladder tumor, a head tumor, a colon tumor, a pancreatic tumor, and a neck tumor.
14 cl, 98 dwg, 20 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2549678C2 |
| COMPOSITIONS OF RECOMBINANT ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES | 2008 |
|
RU2488596C2 |
| COMPOSITIONS OF RECOMBINANT ANTIBODIES FROM EPIDERMAL GROWTH FACTOR RECEPTOR | 2009 |
|
RU2540146C2 |
| TREATMENTS OF CANCER EXPRESSING MUTANT EGF RECEPTORS | 2007 |
|
RU2429014C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF | 2013 |
|
RU2650770C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES | 2016 |
|
RU2728571C2 |
